


Leachianone A

Cat. No.:	HY-N2281
CAS No.:	97938-31-3
Molecular Formula:	C ₂₆ H ₃₀ O ₆
Molecular Weight:	438.51
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8.27 mg/mL (18.86 mM; Need ultrasonic and warming)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
1 mM		2.2804 mL	11.4022 mL	22.8045 mL
5 mM		0.4561 mL	2.2804 mL	4.5609 mL
10 mM		0.2280 mL	1.1402 mL	2.2804 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Leachianone A, isolated from Radix Sophorae, has anti-malarial, anti-inflammatory, and cytotoxic potent^[1]. Leachianone A induces apoptosis involved both extrinsic and intrinsic pathways^[2].

In Vitro

Leachianone A (0-20 µg/ml; 24-72 hours) exhibits a marked inhibition on the survival of HepG2 cells time- and dose-dependently manner, IC₅₀ values are 6.9 µg/ml, 3.4 µg/ml and 2.8 µg/ml in cells with 24-, 48- and 72-hours treatment, respectively^[1].

Leachianone A (10-30 µg/ml; 48 hours) indicates that at low concentration of LA (10 µg/ml), a substantial amount of cells is primarily in the early phase of apoptosis, at higher concentrations, induces a shift of the cell population to late apoptotic/necrotic stage^[1].

Leachianone A (10-30 µg/ml; 48 hours) decreases the precursor of caspase-3 in a dose-dependent manner, reduces the protein level of the pro-forms of upstream initiator caspases, caspases-8 and -9, decreases two downstream substrates, namely inhibitor of caspase-activated DNase (ICAD) and poly-ADP-ribose polymerase (PARP) in HepG2 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HepG2 cells
------------	-------------

	<table border="1"> <tr> <td>Concentration:</td> <td>0 µg/ml, 2 µg/ml, 4 µg/ml, 6 µg/ml, 8 µg/ml, 10 µg/ml, 12 µg/ml, 14 µg/ml, 16 µg/ml, 18 µg/ml, 20 µg/ml</td> </tr> <tr> <td>Incubation Time:</td> <td>24-72 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited HepG2 cells survival.</td> </tr> </table>	Concentration:	0 µg/ml, 2 µg/ml, 4 µg/ml, 6 µg/ml, 8 µg/ml, 10 µg/ml, 12 µg/ml, 14 µg/ml, 16 µg/ml, 18 µg/ml, 20 µg/ml	Incubation Time:	24-72 hours	Result:	Inhibited HepG2 cells survival.		
Concentration:	0 µg/ml, 2 µg/ml, 4 µg/ml, 6 µg/ml, 8 µg/ml, 10 µg/ml, 12 µg/ml, 14 µg/ml, 16 µg/ml, 18 µg/ml, 20 µg/ml								
Incubation Time:	24-72 hours								
Result:	Inhibited HepG2 cells survival.								
	<p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2 cells</td> </tr> <tr> <td>Concentration:</td> <td>48 hours</td> </tr> <tr> <td>Incubation Time:</td> <td>10, 20, and 30 µg/ml</td> </tr> <tr> <td>Result:</td> <td>Induced the proportion of annexin V-stained cells in both the early and late apoptotic stage.</td> </tr> </table>	Cell Line:	HepG2 cells	Concentration:	48 hours	Incubation Time:	10, 20, and 30 µg/ml	Result:	Induced the proportion of annexin V-stained cells in both the early and late apoptotic stage.
Cell Line:	HepG2 cells								
Concentration:	48 hours								
Incubation Time:	10, 20, and 30 µg/ml								
Result:	Induced the proportion of annexin V-stained cells in both the early and late apoptotic stage.								
	<p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2 cells</td> </tr> <tr> <td>Concentration:</td> <td>48 hours</td> </tr> <tr> <td>Incubation Time:</td> <td>10, 20, and 30 µg/ml</td> </tr> <tr> <td>Result:</td> <td>Decreased the protein expression of caspase-3, caspases-8 and -9, reduced ICAD and PARP protein expression.</td> </tr> </table>	Cell Line:	HepG2 cells	Concentration:	48 hours	Incubation Time:	10, 20, and 30 µg/ml	Result:	Decreased the protein expression of caspase-3, caspases-8 and -9, reduced ICAD and PARP protein expression.
Cell Line:	HepG2 cells								
Concentration:	48 hours								
Incubation Time:	10, 20, and 30 µg/ml								
Result:	Decreased the protein expression of caspase-3, caspases-8 and -9, reduced ICAD and PARP protein expression.								
In Vivo	<p>Leachianone A (intravenously injection; 20 mg/kg, 30 mg/kg; once daily; 30 days) significantly diminishes the tumor volume by 17-54% in LA-treated nude mice, when compared with those solely given the vehicle^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male nude mice with human hepatoma HepG2 cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg; 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenously injection; 20 mg/kg, 30 mg/kg; once daily; 30 days</td> </tr> <tr> <td>Result:</td> <td>Suppressed the tumor growth in vivo.</td> </tr> </table>	Animal Model:	Male nude mice with human hepatoma HepG2 cells ^[1]	Dosage:	20 mg/kg; 30 mg/kg	Administration:	Intravenously injection; 20 mg/kg, 30 mg/kg; once daily; 30 days	Result:	Suppressed the tumor growth in vivo.
Animal Model:	Male nude mice with human hepatoma HepG2 cells ^[1]								
Dosage:	20 mg/kg; 30 mg/kg								
Administration:	Intravenously injection; 20 mg/kg, 30 mg/kg; once daily; 30 days								
Result:	Suppressed the tumor growth in vivo.								

REFERENCES

- [1]. Jeong GS, et al. Lavandulyl flavanones from *Sophora flavescens* protect mouse hippocampal cells against glutamate-induced neurotoxicity via the induction of heme oxygenase-1. *Biol Pharm Bull.* 2008 Oct;31(10):1964-7.
- [2]. Cheung CS, et al. Leachianone A as a potential anti-cancer drug by induction of apoptosis in human hepatoma HepG2 cells. *Cancer Lett.* 2007 Aug 18;253(2):224-35. Epub 2007 Mar 26.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA